Dorthe Y.
- Country
- Denmark
- Department
- Department of Oncology
Research Overview
- Evaluation of BT8009 Monotherapy and BT8009 with Pembrolizumab Versus Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
Data & Insights
Has run more than one trial at 33 of 150 partner sites.
Specializations
Oncological Focus
This investigator specializes in treating locally advanced and metastatic urothelial cancer, demonstrating particular expertise in innovative therapeutic approaches for urological malignancies.
- Urological Oncology
- Advanced Cancer Treatment
- Metastatic Disease Management
Treatment Approaches
The investigator focuses on developing combination therapy strategies and evaluating monotherapy treatments for urothelial cancer patients, with expertise in targeted therapeutic interventions.
- Targeted Therapies
- Immunotherapy Applications
- Combination Treatment Protocols
Clinical Assessment
Specializes in evaluating treatment efficacy through response assessment protocols and progression monitoring in advanced urothelial cancer cases.
- Treatment Response Evaluation
- Disease Progression Assessment
- Clinical Outcome Analysis
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.